Pliant Therapeutics Pauses Enrollment in BEACON-IPF Trial, Shares Take Steep Dive
Warning! GuruFocus has detected 3 Warning Signs with PLRX.
The independent Data Safety Monitoring Board of the trial is cited as the reason for the choice.
The suspension, according to the business, will provide time for data assessment and DSMB justification understanding. The study will remain blinded in order to maintain its integrity; patients already enrolled in it will stay in the experiment. Pliant is now alerting worldwide regulatory authorities and has alerted clinical trial investigators.
Targeting ?v?6 and ?v?1 integrins, proteins linked in fibrosis, Bexotegrast is an oral small-molecule inhibitor being studied. The U.S. Food and Drug Administration has assigned it Fast Track and Orphan Drug designations; the European Medicines Agency has assigned it Orphan Drug status. The BEACON-IPF study is assessing the medication as a possible therapy for the progressive lung illness known as idiopathic pulmonary fibrosis, for which there are few therapeutic choices.
Pliant said it is still dedicated to working with authorities and the DSMB to decide the best course ahead, but it did not provide a restarting enrollment timetable. As additional data becomes available, the business said it would provide updates.
This article first appeared on GuruFocus.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Rigetti Stock Falls Despite Quantum Breakthrough
Rigetti Computing (NASDAQ:RGTI) shares slid more than 7% Friday, closing at $16.65 after its second-quarter results underscored just how wide the gap remains between revenue and costs. The company posted revenue of $1.8 million against operating expenses of $20.4 million, while net loss ballooned to $39.7 million. Warning! GuruFocus has detected 5 Warning Signs with RGTI. Nearly $23 million of that came from non-cash charges tied to complex financial instruments. Even with a cash cushion of $571.6 milllion, bolstered by a recent $350 million equity raise, the imbalance weighed on sentiment. Still, Rigetti used the earnings call to showcase its latest quantum leap: the Cepheus-1-36Q system. The 36-qubit machine features a multi-chip design with error rates cut in half compared with the earlier Ankaa-3. Median two-qubit gate fidelity hit 99%, a first for a multi-chip setup, and the system is already live on Rigetti's Quantum Cloud Services and will soon expand to Microsoft (NASDAQ:MSFT) Azure. The chiplet-based approach, first previewed in 2021, now integrates the most chiplets yet in one machine, with faster two-qubit gate speeds and improved couplers. Rigetti said it expects to scale this to 100-plus qubits before the end of 2025, targeting an even higher 99.5% fidelity. For investors, the near-term picture looks pressured by heavy losses, but Rigetti's cash position and progress on its roadmap keep the long-term potential alive. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
Banco do Brasil SA BB Brasil (BDORY) Q2 2025 Earnings Call Highlights: Navigating Growth Amidst ...
Release Date: August 15, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Banco do Brasil SA BB Brasil (BDORY) reported a strong adjusted net income of BRL11.2 million in the first quarter, indicating robust financial performance. The bank's fee income increased by 4.7% compared to the first quarter, showcasing diverse revenue streams supported by its conglomerate companies. The expanded loan portfolio grew significantly, reflecting strong growth in secure lines, particularly for individuals and worker loans. Banco do Brasil SA BB Brasil (BDORY) maintains a strong and robust balance sheet with a CET1 ratio of 10.97%, indicating adequate capital levels. The bank is actively leveraging innovation and artificial intelligence to enhance credit journeys and improve customer experience, preparing for sustainable growth in the coming years. Negative Points The cost of credit increased by 56% compared to the first quarter, driven by agro delinquency and pressure from micro and SMEs. The bank experienced a significant increase in delinquency rates, particularly in the agribusiness sector, reaching unprecedented levels in its history. The need for increased provisions due to Resolution 4,966 has put pressure on the bank's results, impacting profitability. The bank's guidance for 2025 reflects a challenging year of adjustments, with expectations of lower profitability compared to previous years. The agribusiness portfolio faces challenges due to adverse weather events and high leverage, leading to increased delinquency and provisions. Q & A Highlights Warning! GuruFocus has detected 3 Warning Sign with BDORY. Q: How does Banco do Brasil view its CET1 ratio, and what are the plans for maintaining or improving it? A: The CFO, Jovannito BDS, explained that the minimum regulatory CET1 level is 8%, with a prudential target around 11%. As of June, the CET1 was 10.97%, which is considered comfortable. The bank plans to improve net income retention to maintain this level, focusing on resuming profitability to reach the 11% target. There are no current capital restrictions, and the bank is focusing on assets with better risk-adjusted returns to improve retention. Q: What is the strategy for balancing origination and preservation of NII given the new net income guidance? A: CEO Taciana Medeiros stated that the bank aims to grow in lines with better risk-adjusted returns, particularly in the individuals' portfolio. The bank is focusing on secured lines like payroll loans, which offer better margins. Despite higher provisions due to resolution 4,966, the bank is confident in its ability to deliver on its net income guidance by growing margins and increasing NII. Q: Can you provide more details on the agribusiness portfolio and its expected delinquency trends? A: The CEO highlighted that the agribusiness portfolio has been under pressure due to high leverage and adverse weather events. The bank expects productivity and margins to improve, helping to stabilize the portfolio. The goal is to bring delinquency levels back to around 2-2.5% by early 2026, aligning with the end of the current crop cycle. Q: How does the bank plan to handle the provisions for the extended agribusiness portfolio? A: The CRO, Cyril Philippe Prince, explained that the extended portfolio is rigorously managed and related to proven adverse events. The bank is provisioning ahead of time for risks in this portfolio and expects to maintain the same management approach in the coming quarters. The focus is on recovery and collection processes to mitigate risks. Q: What are the expectations for the economic plans' expenses, and how long will they continue? A: The CFO stated that the expenses related to economic plans are expected to continue for another two years, following a recent Supreme Court ruling. The bank aims to conclude these expenses within this timeframe, accelerating agreements to resolve outstanding claims. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
Lockheed Snags $111 Million Navy Deal for Trident Missiles
Lockheed Martin (NYSE:LMT) just locked in a $110.9 million deal with the U.S. Navy to keep building and supporting its Trident II (D5) missiles. The award goes through its space unit and shows how deeply tied Lockheed remains to America's strategic weapons program. Warning! GuruFocus has detected 6 Warning Signs with LMT. Most of the work will happen in Magna, Utah, and it's set to run all the way until Sept. 30, 2029. This wasn't a wide-open competition either Lockheed was the only bidder, which isn't surprising given its long history as the Navy's go-to partner on Trident. For investors, it's another steady win that underscores the company's position in defense contracts. These types of long-term awards bring visibility to Lockheed's revenue pipeline and keep missile systems a core growth driver. This article first appeared on GuruFocus.
